Valeant Includes OTCs In Bid For Dramatic Growth By 2013
By
Dan Schiff / Email the Author / “The Tan Sheet” Jan. 23, 2012, Vol. 20, No. 04
Business & Finance / Word Count: 715 / Article # 05120123003
Executive Summary
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.